市場調查報告書
商品編碼
1563127
全球類器官市場:依產品和服務、類器官類型、應用、最終用戶和地區的預測(~2032年)Global Organoids Market Research Report Information By Product and Service, By Type of Organoids, By Application, By End-Users And By Region -Forecast Till 2032 |
類器官市場規模預計將從2023年的13.9億美元,2024年的16.8億美元,到2032年將成長到91.6億美元,預測期內年複合成長率為23.55%。由於對個人化醫療的需求不斷成長以及藥物發現和毒理學研究的應用不斷增加,該市場不斷成長。
類器官市場是由個人化醫療需求不斷成長所推動的。精準醫療,也稱為個人化醫療,其特點是根據每個患者的特徵進行客製化治療。該方法目的是透過考慮基因組成、環境和生活方式等因素來提供更有效、更有針對性的治療。類器官是推動個人化醫療的重要工具,因為它們是模仿器官功能和複雜性的微型3D組織結構。
承認個體對治療的反應存在巨大差異是個人化醫療的關鍵要素。儘管動物模型和二維細胞培養經常用於傳統藥物開發,但它們並不能準確反映人類生物學。類器官為研究疾病機制和評估藥物反應提供了一個更生理相關的平台。透過利用源自患者的類器官,研究人員可以更全面地了解疾病的特徵,並預測個體對不同治療的反應。
依地域的展望
北美地區將在2023年佔據最大的市場佔有率,預測期內年複合成長率為 22.88%,預計到2032年將增至 34.2億美元的規模。
技術的進步促進了 3D 類器官和球體的開發,增加了美國和加拿大生物技術領域基於類器官的研究模型的使用。美國領先的學術研究機構和生物技術公司一直處於類器官技術不斷進步的前沿。
歐洲是僅次於北美的第二大市佔率。歐洲對生命科學的大量投資和強大的研究基礎設施是關鍵因素。處於類器官研究前沿的知名研究機構和生物技術公司位於英國、德國、荷蘭等國家。
亞太地區經歷顯著成長。這是由多種顯著因素所驅動的。類器官是源自幹細胞和組織的小型3D器官,有潛力用於再生醫學應用、藥物發現和疾病建模。
本報告調查了全球類器官市場,提供市場的定義和概述,市場成長的各種影響因素分析,市場規模推移和預測,各種區分、地區的細分,競爭環境,主要企業概況等彙整資料。
Global Organoids Market Research Report Information By Product and Service (Product and Service), By Type of Organoids (Liver, Kidney, Pancreas, Intestine, Heart, and others), By Application (Drug Testing, Developmental Biology, Personalized Medicine, Regenerative Medicine, and Others), By End-Users (Academic and Research Institutes, Pharmaceutical and Biotechnology Company, Contract Research Organizations (CROs), and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) -Forecast Till 2032
In 2023, the Organoids Market was estimated to be worth USD 1.39 billion. The industry is anticipated to experience a compound annual growth rate (CAGR) of 23.55% from USD 1.68 billion in 2024 to USD 9.16 billion by 2032 during the forecast period (2024-2032). The market is experiencing growth due to the increasing demand for personalized medicine and the increasing application of drug discovery and toxicology studies.
The Organoids Market is being driven by the increasing demand for personalized medicine. Precision medicine, which is also referred to as personalized medicine, is characterized by the customization of medical treatment to the unique characteristics of each patient. This method is designed to deliver more effective and targeted therapies by taking into account factors such as genetic composition, environment, and lifestyle. Organoids are a critical instrument in the advancement of personalized medicine, as they are miniature 3D tissue structures that replicate the functionality and complexity of organs.
The acknowledgment of the significant variability in the way individuals respond to treatments is a critical component of personalized medicine. Animal models or 2D cell cultures are frequently employed in conventional drug development methods, but they do not accurately reflect human biology. Organoids provide a more physiologically relevant platform for the investigation of disease mechanisms and the assessment of drug responses. Researchers can gain a more comprehensive understanding of the distinctive characteristics of diseases and predict the responses of individuals to various treatments by utilizing patient-derived organoids.
Market segment insights
The Organoids Market has been segmented into product and service based on product and service.
The Organoids Market has been segmented into the following categories: Liver, Kidney, Pancreas, Intestine, Heart, and Others according to the variety of organoids.
The Market has been segmented into Drug Testing, Developmental Biology, Personalized Medicine, Regenerative Medicine, and Others, as determined by its application.
The Market has been segmented into Academic and Research Institutions, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), and others based on End-Users.
Regional Perspectives
The Organoids Market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World based on region. In 2023, North America held the largest market share, which is expected to increase to USD 3.42 billion by 2032, representing a compound annual growth rate (CAGR) of 22.88% during the forecast period.
Advancements in technology have facilitated the development of 3D organoids and spheroids, which have contributed to the rise in the use of organoid-based research models in the biotechnology sector of the United States and Canada. Major academic research institutions and biotechnology companies in the United States have been at the vanguard of the ongoing advancement of organoid technology.
Europe is the second-largest organoid market share, following the Americas region. Europe's substantial investment in life sciences and robust research infrastructure are significant factors. Renowned research institutions and biotechnology corporations that are at the forefront of organoid research are located in countries such as the United Kingdom, Germany, and the Netherlands.
The organoids market in the Asia Pacific region is experiencing substantial growth, which is being promoted by a variety of notable factors. Organoids, miniaturized organs that are three-dimensional and are derived from stem cells or tissue, have the potential to be used in regenerative medicine applications, drug discovery, and disease modeling.
Merck KGgA, Corning Incorporated, STEMCELL Technologies, Bio-Techne, Molecular Devices, LLC, and Thermo Fisher Scientific Inc. are among the major participants in the Organoids Market.